Role of EphB3 Receptor in Mediating Head and Neck Tumor Growth, Cell Migration, and Response to PI3K Inhibitor.

Abstract

Eph proteins have emerged as critical drivers affecting tumor growth and progression in human malignancies. Our The Cancer Genome Atlas (TCGA) data analysis showed that EphB3, a receptor tyrosine kinase, is frequently coamplified with PIK3CA in head and neck squamous cell carcinoma (HNSCC). We therefore hypothesized that EphB3 amplification plays a protumorigenic role in HNSCC and that EphB3 and PIK3CA are cooperating oncogenes that contribute toward its pathogenesis. This hypothesis was not experimentally supported, because EphB3 knockdown failed to alter HNSCC tumor cell growth in vitro or in vivo with an orthotopic model. However, responsiveness of EphB3 knockdown tumors to the PI3K inhibitor, BKM120, was significantly decreased in terms of both tumor growth delay and survival. This is correlated with an increase in prosurvival proteins, S6 and BcL-XL, in the EphB3 shRNA tumors treated with BKM120 compared with controls. We further observed that EphB3 knockdown resulted in increased migration in vitro and increased EMT gene signature in vivo To explain these results, we examined EphB3 phosphorylation levels in HNSCC at baseline. Although total EphB3 levels were high, we found low phospho-EphB3 levels in HNSCCs. Forced EphB3 phosphorylation with an ephrin-B2-Fc fusion protein resulted in decreased HNSCC migration and cell growth, and enhanced response to BKM120 in vitro These data collectively indicate that progression of HNSCC selects for low/inhibited EphB3 activity to enhance their survival and migratory abilities and decrease response to PI3K signaling. Therefore, strategies focused on activating EphB3 might be helpful to inhibit tumor growth and enhance sensitivity to PI3K inhibitors in HNSCC. Mol Cancer Ther; 17(9); 2049-59. ©2018 AACR.

• Authors: Shilpa Bhatia, Anastacia Griego, Shelby Lennon, Ayman Oweida, Jaspreet Sharma, Christina Rohmer, Nomin Uyanga, Sanjana Bukkapatnam, Benjamin Van Court, David Raben, Christian Young, Lynn Heasley, Sana D Karam
• Journal: Molecular cancer therapeutics (Mol Cancer Ther) Vol. 17 Issue 9 Pg. 2049-2059 (09 2018) ISSN: 1538-8514 [Electronic] United States
• PMID: 29970482 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
• Copyright: ©2018 American Association for Cancer Research.

Chemical References

• Aminopyridines
• Morpholines
• NVP-BKM120
• Class I Phosphatidylinositol 3-Kinases
• PIK3CA protein, human
• Receptor, EphB3

Topics

• Aminopyridines (pharmacology)
• Animals
• Carcinoma, Squamous Cell (drug therapy, genetics, metabolism)
• Cell Line, Tumor
• Cell Movement (drug effects, genetics)
• Class I Phosphatidylinositol 3-Kinases (antagonists & inhibitors, genetics, metabolism)
• Female
• Head and Neck Neoplasms (drug therapy, genetics, metabolism)
• Humans
• Kaplan-Meier Estimate
• Mice, Nude
• Morpholines (pharmacology)
• RNA Interference
• Receptor, EphB3 (genetics, metabolism)
• Signal Transduction (drug effects, genetics)
• Tumor Burden (drug effects, genetics)
• Xenograft Model Antitumor Assays (methods)